Ondine Biomedical Introduces Nasal Photodisinfection to Quebec through MAM Medical Inc.

MAM Medical to bring Ondine’s breakthrough infection prevention product to Quebec

VANCOUVER, BC, Canada – Apr. 29, 2019

Ondine Biomedical Inc. announced today it has entered into an exclusive agency agreement with MAM Medical Inc. to represent Ondine’s patented nasal Photodisinfection, MRSAid™, to healthcare providers in Quebec.

Deployed in hospitals in British Columbia, Ondine’s nasal Photodisinfection has proven to significantly reduce surgical site infections by eradicating a broad spectrum of infection-causing pathogens that reside in the noses of patients and caregivers, from where they are easily transmitted to wounds, surgical sites, hospital surfaces, and other patients.

Vancouver Coastal Health findings from an 8-year evaluation of Ondine’s nasal Photodisinfection were presented at the 2019 Canadian Spine Society Annual Conference in Toronto in an abstract titled “Efficacy and Cost-Effectiveness of Photodynamic Therapy in Prevention of Surgical Site Infections.” The VCH study team, led by Drs. John Street, Titus Wong, Daniel Banaszek, Tom Inglis and Vancouver Spine Institute program surgeons, found that employment of a universal pre-surgical bundle featuring Ondine’s nasal Photodisinfection resulted in 78% reduction of spine surgical site infection rates (from 7.2% to 1.6%, p<0.01, NNT=18). Study authors estimated 53 infections were avoided per year, at an annual cost savings of $4.24 million with no adverse events, leading to a recommendation to use nasal Photodisinfection for all spine surgeries in Canada.

“We are extremely excited about Ondine’s Photodisinfection technology and the results we have seen reported to the Canadian Spine Society. Knowing the growing threats to patients from antimicrobial resistance, we are very keen to start introducing this important new technology into the Quebec market,” said Marc Joannette, President and Founder, MAM Medical. “With our relationships in the operating rooms across the province of Quebec, the MAM team, partnering with Ondine, will be part of a new era of medical care and patient safety. We will change the way we prepare patients for surgery and strongly impact surgical outcomes,” stated Dominic Rhéaume, MAM Medical, Partner.

“Ondine is delighted to be expanding its sales coverage and distribution into the province of Quebec. With its passion for promoting best clinical practices and superior patient outcomes, MAM Medical is an ideal partner for our life-saving technology. Together, we hope to make a meaningful impact on patient safety in Quebec by reducing the potential for life-threatening infections from multidrug-resistant pathogens in patients undergoing surgery, in intensive care units, undergoing dialysis, or otherwise immunocompromised,” said Michelle Anschuetz, Chief Commercial Officer, Ondine Biomedical, Inc.

About Ondine’s Nasal Photodisinfection

Ondine’s patented nasal Photodisinfection is a powerful, light-activated antimicrobial developed to eradicate a broad spectrum of infection-causing pathogens that reside in the noses of patients and caregivers and are easily transmitted from there to wounds, surgical sites, hospital surfaces, and other patients. In four minutes of treatment, it decolonizes nasal pathogens, including drug-resistant bacteria (i.e. MRSA, MSSA), viruses, and fungi (i.e. aspergillus, Candida auris). Because Photodisinfection is effective against such a broad spectrum of pathogens and does not generate antimicrobial resistance, expensive and time-consuming pathogen identification is not required. Photodisinfection kills microbes through oxidative disruption of the microbial cell membrane with no known adverse effects to human epithelial tissue or mucosa. Microbes are unable to resist or adapt to this treatment.

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is dedicated to the development of treatment and prevention therapies for a broad-spectrum of multidrug-resistant bacterial, viral and fungal infections. Ondine’s antimicrobial program utilizes a platform technology called Photodisinfection, a light-activated approach for use in humans being developed to provide rapid antimicrobial efficacy without elevating risk of resistance. In addition to Ondine’s nasal Photodisinfection therapy, other applications of the Photodisinfection platform are under development, including treatment of chronic rhinosinusitis, treatment of burns and wounds, and disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia.

About MAM Medical Inc.

MAM Medical Inc. is a privately-owned Quebec-based company established in 2005 that specializes in providing leading-edge medical device technologies to operating rooms. MAM Medical prides itself in hiring the brightest and most competent sales force in the orthopaedic market in Quebec, bringing valuable experience in immunology, virology, and experimental medicine.

Contacts:
Ondine Biomedical Inc.
www.ondinebio.com
Angelika Vance, Director – Corporate Development
avance@ondinebio.com
T. 1.604.838.2702

MAM Medical Inc.
Marc Joannette, President
marc.joannette@mammedical.com
T. 1.450.907.4626

Share this post via Email
Share this post on Twitter
Share this post on LinkedIn
Print PDF of this post